27.02.2020 Elanix Biotechnologies AG  DE000A0WMJQ4

DGAP-Adhoc: ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD Biotechnologies AG:


 

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Legal Matter
ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD Biotechnologies AG:

27-Feb-2020 / 12:19 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


ELANIX BIOTECHNOLOGIES AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD

Frankfurt, 27 February 2020 - The Vice Chairman of the Supervisory Board Fang Bao and a member of the Supervisory Board, Prof. Zhanfeng Cui notified the CEO that they resigned from the office due to work commitments.
The Management Board would like to thank Ms. Fang Bao and Prof. Cui for their work in the Supervisory Board.

The District Court in Berlin has appointed successors, following the Board's proposal of two suitable candidates.

The Supervisory Board of Elanix Biotechnologies AG ("Company", "Elanix") has nominated by juridical order Marco Christen and Yves Bonnard to become members of the Supervisory Board with immediate effect.

Today, the Supervisory Board of Elanix has re-elected Anja Silling to remain the Chairman of the Board and Marco Christen, to be the Vice Chairman.

Lee-Ann Laurent-Applegate
interim CEO


27-Feb-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
60314 Frankfurt am Main
Germany
Internet: www.elanixbiotechnologies.ch
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard)
EQS News ID: 984999

 
End of Announcement DGAP News Service

984999  27-Feb-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=984999&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA1,2 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT1,4 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer:

INVESTOR-INFORMATIONEN
©boersengefluester.de
WKN Kurs in € Einschätzung Börsenwert in Mio. €
0,000 0,00
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 0,00
KBV KCV KUV EV/EBITDA
0,00 0,00 0,00 0,00
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
0,00% 0,00% 0,00% 0,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Elanix Biotechnologies AG  ISIN: DE000A0WMJQ4 können Sie bei DGAP abrufen

Biotechnologie , A0WMJQ , ELN , FWB:ELN